FDA grants breakthrough status to Biogen’s litifilimab for CLE

The FDA based its decision on comprehensive data, including findings from the Phase II LILAC study. Credit: Sai Thaw Kyar / Shutterstock.com.



  • FDA Biogen’s litifilimab